Product
TIL Transfer with anti-PD-1 Therapy and low dose IL-2
1 clinical trial
1 indication
Indication
MelanomaClinical trial
A Phase I Study of Adoptive Tumor-infiltrating Lymphocyte Transfer in Combination With Nivolumab in Patients With Advanced MelanomaStatus: Completed, Estimated PCD: 2023-03-30